Table 2.
Cox regression for overall survival and time to treatment failure in patients receiving systemic treatment after diagnosis of metastatic disease.
| Overall survival | Time-to-treatment failure | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events | Median OS (months) | Univariable regression | Multivariable regressiona,b | Events | Median TTF (months) | Univariable regression | Multivariable regressiona,b | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |||||
| Synchronous | 1269 | 8.8 | Ref | Ref | 1222 | 6.1 | Ref | Ref | ||||
| Early metachronous | 42 | 4.5 | 1.75 (1.29–2.38) | <0.001 | 1.70 (1.23–2.36) | 0.001 | 43 | 3.8 | 1.96 (1.44–2.65) | <0.001 | 1.89 (1.37–2.61) | <0.001 |
| Late metachronous | 177 | 9.1 | 0.96 (0.82–1.12) | 0.59 | 1.00 (0.84–1.20) | 0.99 | 161 | 5.7 | 0.97 (0.82–1.14) | 0.70 | 1.01 (0.84–1.21) | 0.93 |
CI, confidence interval; HR, hazard ratio; OS, overall survival; TTF, time to treatment failure.
Patients receiving radical treatment of primary tumor, locoregional recurrence, or distant metastases in addition to systemic therapy were excluded.
Adjusted for gender, age, number of comorbidities, tumor location at primary diagnosis, cT stage at primary diagnosis, cN stage at primary diagnosis, Lauren’s classification at primary diagnosis, tumor differentiation at primary diagnosis, number of metastatic sites, location of metastases (distant lymph nodes, liver metastases, lung, bone, peritoneal, and other), and receiving a trastuzumab-containing regimen.
Performance status did not meet the proportional hazard assumptions and the models were stratified for this covariate.